Serum Aminotransferase Flares in Pregnant and Postpartum Women with Current or Prior Treatment for Chronic Hepatitis B

Journal of Clinical Gastroenterology

Volumn 52, Issue 3, 2018, Pages 255-261

  Chang, Christine Y ^a,b   Aziz, Natali ^c   Poongkunran, Mugilan ^e   Javaid, Asad ^e   Trinh, Huy N ^d   Lau, Daryl T ^e   Nguyen, Mindie H ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d San Jose Gastroenterology   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

antiviral therapy; chronic hepatitis B; hepatic flare; pregnancy

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; ANTIVIRUS AGENT; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS B; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; ICD-9; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PREGNANT WOMAN; PREVALENCE; PRIORITY JOURNAL; PUERPERIUM; RETROSPECTIVE STUDY; THIRD TRIMESTER PREGNANCY; TREATMENT DURATION; TREATMENT OUTCOME; VAGINAL DELIVERY; BLOOD; CLINICAL TRIAL; HEPATITIS B VIRUS; ISOLATION AND PURIFICATION; PREGNANCY; PREGNANCY COMPLICATION; SEVERITY OF ILLNESS INDEX; TIME FACTOR; VIROLOGY;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 85015744335     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000822     Document Type: Article

References (32)

1. World Health Organization. Hepatitis B. World Health Organization Fact Sheet 204. (Revised July 2016) http://who. int/mediacentre/factsheets/fs204/en/. Accessed August 1, 2016.
2. Din ES, Wasley A, Jacques-Carroll L, et al. Estimating the number of births to hepatitis B virus-infected women in 22 states, 2006. Pediatr Infect Dis J. 2011;30:575-579.
3. Lin C-C, Hsieh H-S, Huang Y-J, et al. Hepatitis B virus infection among pregnant women in Taiwan: comparison between women born in Taiwan and other southeast countries. BMC Public Health. 2008;8:49.
4. Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol. 2004;5: 66-271.
5. Giles ML, Visvanthan K, Lewin SR, et al. Chronic hepatitis B infection and pregnancy. Obstet Gynecol Surv. 2012;67:37-44.
6. Lin HH, Chen PJ, Chen DS, et al. Postpartum subsidence of hepatitis B viral replication in HBeAg-positive carrier mothers. J Med Virol. 1989;29:1-6.
7. Ter Borg MJ, Leemans WF, De Man RA, et al. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat. 2008;15:37-41.
8. Giles M, Visvanathan K, Lewin S, et al. Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B. Gut. 2015;64:1810-1815.
9. Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009;16:94-103.
10. Nguyen V, Tan PK, Greenup a J, et al. Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare. Aliment Pharmacol Ther. 2014;39:1225-1234.
11. Nguyen G, Garcia RT, Nguyen N, et al. Clinical course of hepatitis B virus infection during pregnancy. Aliment Pharmacol Ther. 2009;29:755-764.
12. Terrault NA, Bzowej NH, Chang K-M, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261-283.
13. Wang L, Kourtis AP, Ellington S, et al. Safety of tenofovir during pregnancy for the mother and fetus: a systematic review. Clin Infect Dis. 2013;57:1773-1781.
14. Kelly E, Peters MG. Management of HBV in pregnancy. Curr Hepatol Reports. 2015;14:145-152.
15. Brown RS, Verna EC, Pereira MR, et al. Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry. J Hepatol. 2012; 57:953-959.
16. Pirillo MF, Scarcella P, Andreotti M, et al. Hepatitis B virus mother-to-child transmission among HIV-infected women receiving lamivudine-containing antiretroviral regimens during pregnancy and breastfeeding. J Viral Hepat. 2015; 22:289-296.
17. Liu J, Wang J, Jin D, et al. Hepatic flare after telbivudine withdrawal and efficacy of postpartum antiviral therapy for pregnancies with chronic HBV. J Gastroenterol Hepatol. 2017;32:177-183.
18. Orasan OH, Iancu M, Sava M, et al. Non-invasive assessment of liver fibrosis in chronic viral hepatitis. Eur J Clin Invest. 2015;45:1243-1251.
19. Brown RS, McMahon BJ, Lok ASF, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. Hepatology. 2016;63: 319-333.
20. Sö derström A, Norkrans G, Lindh M. Hepatitis B virus DNA during pregnancy and post partum: aspects on vertical transmission. Scand J Infect Dis. 2003;35:814-819.
21. Zhang H, Pan CQ, Pang Q, et al. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology. 2014;60:468-476.
22. Chen H-L, Lee C-N, Chang C-H, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-toinfant transmission of hepatitis B virus. Hepatology. 2015;62: 375-386.
23. Coffin CS, Lee SS. Editorial: anti-viral therapy for prevention of perinatal HBV transmission-extending therapy beyond birth and the risk of post-partum flare. Aliment Pharmacol Ther. 2014;40:115-116.
24. He T, Jia J. Chronic HBV: Which pregnant women should be treated? Liver Int. 2016;36:105-108.
25. Liu M, Cai H, Yi W. Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy. J Viral Hepat. 2013;20:65-70.
26. Su G, Pan K, Zhao N, et al. Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. J Gastroenterol. 2004;10:910-912.
27. Chang M-L, Liaw Y-F. Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management. J Hepatol. 2014;61:1407-1417.
28. Kim HY, Choi JY, Park C, et al. Outcome after discontinuing antiviral agents during pregnancy in women infected with hepatitis B virus. J Clin Virol. 2013;56:299-305.
29. Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374:2324-2334.
30. Ehrhardt S, Xie C, Guo N, et al. Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence. Clin Infect Dis. 2014;60:275-278.
31. Lin HH, Wu WY, Kao JH, et al. Hepatitis B post-partum e antigen clearance in hepatitis B carrier mothers: Correlation with viral characteristics. J Gastroenterol Hepatol. 2006;21:605-609.
32. Pan CQ, Han GR, Jiang HX, et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol. 2012;10:520-526.